Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
SRN-820
- Development stage
- Preclinical
- Lead developer
- Seragon Biosciences
- Modality
- Small Molecules
- Administration
- Oral
01
Overview
SRN-820 is an experimental compound developed by Seragon Biosciences as part of its longevity and anti-aging research program. It is identified as a constituent of the combinatorial drug candidate SRN-901, which is designed to target multiple biological pathways associated with aging to extend healthy lifespan. Seragon's research into SRN-820 focuses on its potential to modulate aging markers, although specific details regarding its chemical structure, individual molecular target, and standalone therapeutic profile have not been publicly disclosed. The compound is currently in the early stages of development, primarily as part of the SRN-901 formulation.
Beyond the preview
Go deeper on SRN-820.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on SRN-820.